With the proliferation of diabetes around the globe, ophthalmologists located in countries that are treating diabetic retinopathy and diabetic macular edema (DME) more often now are in need of detailed guidelines to assist them.
Throughout the body, any source of cellular damage (e.g., inflammation, infection, smoking, or high blood sugar) can liberate reactive oxygen species and set in motion an oxidative stress chain reaction that ultimately leads to tissue dam
First-line treatment for diabetic macular edema (DME) is overwhelmingly anti-vascular endothelial growth factor (VEGF) drugs, with more than two-thirds of clinicians around the world prescribing them for this patient population.
Diabetic eye disease is occurring in younger populations, which means it's time to rethink anti-VEGF standards.
An analysis of data from the FAME trials was undertaken to try to understand the final three-year visual and anatomic outcomes of patients treated with the fluocinolone acetonide intravitreal implant (Iluvien, Alimera Sciences) who exhibi
Retinal vein occlusions (RVOs) are a frequent cause of retinal vascular disease in patients older than 50 years.
Compared with intravitreous ranibizumab, the decreases in the plasma-free VEGF levels were greater with intravitreous aflibercept and bevacizumab in patients with diabetic macular edema.
Among a subset of patients in the phase IV PALADIN study, there was improved visual acuity, improved macular thickness, and reduced treatment burden among patients treated with the intravitreal fluocinolone acetonide 0.2 µg (Iluvien implant) for DME.
The addition of dexamethasone implant (Ozurdex, Allergan) to a continuing regimen of ranibizumab (Lucentis, Genentech) did not produce results in visual acuity outcomes that differed from those achieved with ranibizumab alone at 6 months. However, there was an improvement in the central macular thickness on OCT in patients.
The use of aflibercept led to greater improvement in macular perfusion status in a phase III trial with DME patients. Those with baseline nonperfusion tended to have more advanced disease.